Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | UBE2N | P61088 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safingol SCHEMBL5061324 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1900812 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Dihydrospingosine SCHEMBL12563458 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Safingol SCHEMBL6772 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131930 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL12330738 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131985 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21660227 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21431064 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL18127645 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025032499-A2 | METHOD FOR THE ISOLATION OF GLYCOSPHINGOLIPIDS | CARBOCODE S.A. (PT) | 2025-02-13 | — | — | WO | claimed |
| CN-109596748-B | Method for detecting metabolites of gandi capsules for treating diabetic nephropathy patients | 上海交通大学医学院附属新华医院 | 2022-03-04 | — | — | CN | claimed |
| US-20210148933-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-05-20 | — | — | US | claimed |
| EP-3773919-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-02-17 | — | — | EP | claimed |
| WO-2019186141-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2019-10-03 | — | — | WO | claimed |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4720029-A1 | LIPID BLENDS | Cataya Bio (Shanghai) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | REFLECTION BIOTECHNOLOGIES LIMITED (HK) | 2026-03-31 | — | — | US | disclosed |
| EP-4591884-A1 | LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, AND RELATED USE AND MEDICAMENT COMPRISING SAME | Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd. (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025133966-A1 | PRODUCTION OF GLUCOSYLCERAMIDE | CARBOCODE S.A (PT) | 2025-06-26 | — | — | WO | disclosed |
| CN-111630170-B | Cellular model of ocular disease and therapy for ocular disease | 映像生物有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025032497-A1 | SIALYLATION METHOD | CARBOCODE S.A. (PT) | 2025-02-13 | — | — | WO | disclosed |
| US-11479798-B2 | Recombinant host cell with altered membrane lipid composition | BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT) | 2022-10-25 | — | — | US | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |
| US-20220125838-A1 | IMMUNOMODULATORY GLYCOSPHINGOLIPIDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210148933-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3773919-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019186141-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019185038-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | 中国医学科学院基础医学研究所 | 2019-10-03 | — | — | WO | disclosed |
| US-20150045291-A1 | LIPOPEPTIDE CONJUGATES COMPRISING SPHINGOLIPID AND HIV GP41 DERIVED PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | CYP2D6 4264/4885SPHK1 8/4885LMNA 77/4885 |
| US-20220125838-A1 | IMMUNOMODULATORY GLYCOSPHINGOLIPIDS AND METHODS OF USE THEREOF | UGCG, B3GAT3, GALC | CYP2D6 4646/4885SPHK1 111/4885LMNA 1471/4885 |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | ALDH1A2, NR2E3, RBP4 | CYP2D6 155/4885SPHK1 4875/4885LMNA 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.